Last reviewed · How we verify
NCT06980623
Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction
trial testing Tirzepatide in Type 2 Diabetes in 26,000 participants. Participants enrolled and being followed up; not accepting new ones.
30 November 2025
Quick facts
| Lead sponsor | Brigham and Women's Hospital |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 26,000 |
| Start date | 1 January 2025 |
| Primary completion | 30 November 2025 |
| Estimated completion | 1 October 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Tirzepatide (TIRZEPATIDE) — full drug profile →
- Semaglutide (semaglutide) — full drug profile →
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
- Heart Failure — all drugs for Heart Failure →
Sponsor
Brigham and Women's Hospital
Who can join
18 and older, any sex, with Type 2 Diabetes or Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This cohort study aims to assess the comparative effectiveness of tirzepatide versus semaglutide with respect to cardiovascular events in patients with type 2 diabetes and heart failure with preserved ejection fraction.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials.
Harbi MH, Ashour AM, Alorfi NM, Aldurdunji MM, et al · · 2026 · PMID 42100257 · DOI 10.3389/fmed.2026.1764664
Verify or expand the search:
- PubMed search for NCT06980623
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tirzepatide
Trials testing the same drug.
- NCT07468552 — Trial of Tirzepatide for the Treatment of Cannabis Use Disorder · Phase 2 · not yet recruiting
- NCT06732245 — Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese · Phase 2 · not yet recruiting
- NCT07349641 — A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia · Phase 2 · not yet recruiting
- NCT07265752 — Tirzepatide for the Treatment of Cannabis Use Disorder · Phase 2 · not yet recruiting
- NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other Brigham and Women's Hospital trials
Trials by the same sponsor.
- NCT07011758 — Dynamic Treatment Regimes for Opioid Use Disorder · Phase 2 · not yet recruiting
- NCT06310018 — Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE · suspended
- NCT04519177 — Randomized Trial of a Sleep Disorders Program on Firefighter Safety and Disability ... · NA · not yet recruiting
- NCT06355986 — Computerized Decision Support to Prevent Stroke in Atrial Fibrillation · NA · not yet recruiting
- NCT06099275 — Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06980623 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Brigham and Women's Hospital
- Last refreshed: 12 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06980623.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing